CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance

Coronavirus disease-2019 (COVID-19), as a worldwide serious issue has been shown to lead to progression and poor outcomes in cancer patients. The underlying mechanisms for SARS-CoV-2 infection’s adverse effects on cancer patients have not been fully understood. We hypothesized that CD147 and Cycloph...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakhtiyari, Maryam, Haji Aghasi, Ayda, Banihashemi, Sara, Abbassioun, Arian, Tavakol, Chanour, Zalpoor, Hamidreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072013/
https://www.ncbi.nlm.nih.gov/pubmed/37016434
http://dx.doi.org/10.1186/s13027-023-00501-2
_version_ 1785019300353933312
author Bakhtiyari, Maryam
Haji Aghasi, Ayda
Banihashemi, Sara
Abbassioun, Arian
Tavakol, Chanour
Zalpoor, Hamidreza
author_facet Bakhtiyari, Maryam
Haji Aghasi, Ayda
Banihashemi, Sara
Abbassioun, Arian
Tavakol, Chanour
Zalpoor, Hamidreza
author_sort Bakhtiyari, Maryam
collection PubMed
description Coronavirus disease-2019 (COVID-19), as a worldwide serious issue has been shown to lead to progression and poor outcomes in cancer patients. The underlying mechanisms for SARS-CoV-2 infection’s adverse effects on cancer patients have not been fully understood. We hypothesized that CD147 and Cyclophilin A (CyPA) not only can play a significant role in infection severity but also can contribute to cancer progression and chemotherapy resistance in cancer patients with COVID-19. In addition, we hypothesized that the expression of both CD147 and CyPA could be increased by Hypoxia-inducible Factor-1 alpha (HIF-1α) activation during hypoxic conditions that occurred during COVID-19. Therefore, this evidence can open a new window in the management of cancer patients during the pandemic and therapeutic approaches targeting CD147 and CyPA could be a potentially promising therapeutic approach for such patients.
format Online
Article
Text
id pubmed-10072013
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100720132023-04-04 CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance Bakhtiyari, Maryam Haji Aghasi, Ayda Banihashemi, Sara Abbassioun, Arian Tavakol, Chanour Zalpoor, Hamidreza Infect Agent Cancer Correspondence Coronavirus disease-2019 (COVID-19), as a worldwide serious issue has been shown to lead to progression and poor outcomes in cancer patients. The underlying mechanisms for SARS-CoV-2 infection’s adverse effects on cancer patients have not been fully understood. We hypothesized that CD147 and Cyclophilin A (CyPA) not only can play a significant role in infection severity but also can contribute to cancer progression and chemotherapy resistance in cancer patients with COVID-19. In addition, we hypothesized that the expression of both CD147 and CyPA could be increased by Hypoxia-inducible Factor-1 alpha (HIF-1α) activation during hypoxic conditions that occurred during COVID-19. Therefore, this evidence can open a new window in the management of cancer patients during the pandemic and therapeutic approaches targeting CD147 and CyPA could be a potentially promising therapeutic approach for such patients. BioMed Central 2023-04-04 /pmc/articles/PMC10072013/ /pubmed/37016434 http://dx.doi.org/10.1186/s13027-023-00501-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Bakhtiyari, Maryam
Haji Aghasi, Ayda
Banihashemi, Sara
Abbassioun, Arian
Tavakol, Chanour
Zalpoor, Hamidreza
CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance
title CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance
title_full CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance
title_fullStr CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance
title_full_unstemmed CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance
title_short CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance
title_sort cd147 and cyclophilin a: a promising potential targeted therapy for covid-19 and associated cancer progression and chemo-resistance
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072013/
https://www.ncbi.nlm.nih.gov/pubmed/37016434
http://dx.doi.org/10.1186/s13027-023-00501-2
work_keys_str_mv AT bakhtiyarimaryam cd147andcyclophilinaapromisingpotentialtargetedtherapyforcovid19andassociatedcancerprogressionandchemoresistance
AT hajiaghasiayda cd147andcyclophilinaapromisingpotentialtargetedtherapyforcovid19andassociatedcancerprogressionandchemoresistance
AT banihashemisara cd147andcyclophilinaapromisingpotentialtargetedtherapyforcovid19andassociatedcancerprogressionandchemoresistance
AT abbassiounarian cd147andcyclophilinaapromisingpotentialtargetedtherapyforcovid19andassociatedcancerprogressionandchemoresistance
AT tavakolchanour cd147andcyclophilinaapromisingpotentialtargetedtherapyforcovid19andassociatedcancerprogressionandchemoresistance
AT zalpoorhamidreza cd147andcyclophilinaapromisingpotentialtargetedtherapyforcovid19andassociatedcancerprogressionandchemoresistance

Ejemplares similares